Section 1833(i)(9) of the Act requires under the ASC payment system that, in the case of a Part B rebatable drug for which payment is not packaged into a payment for a service, in lieu of calculation of coinsurance that would otherwise apply under the ASC payment system, the provisions of section 1847A(i)(5) of the Act shall, as determined appropriate by the Secretary, apply for calculation of beneficiary coinsurance in the same manner as the provisions of section 1847A(i)(5) of the Act apply under that section
Adenosylcobalamin functions in mitochondria as a cofactor for methylmalonyl-CoA mutase
One honest caveat up front, because it shapes everything below: the evidence base for 5-Amino-1MQ is almost entirely preclinical mouse and cell-culture studies
Species-specific factors profoundly influence both efficacy and safety profiles
A commercial category is not a scientific category Inclusion in a Peptides UK catalogue does not turn 5-Amino-1MQ into a peptide and does not establish that it is suitable for human administration
The last time he ate it, he ended up loose as a goose